Literature DB >> 16447242

Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia.

Sarah R Atkins1, Carl Turesson, Jeffery L Myers, Henry D Tazelaar, Jay H Ryu, Eric L Matteson, Tim Bongartz.   

Abstract

OBJECTIVE: B lymphocytes are emerging as important elements in the events leading to joint destruction in rheumatoid arthritis (RA). However, B lymphocytes have not been studied in rheumatoid arthritis (RA)-associated lung disease. We performed a morphologic and quantitative analysis of B lymphocytes and plasma cells in RA-associated interstitial pneumonia (IP) in comparison with idiopathic IP and normal lungs.
METHODS: Open-lung biopsy specimens from patients with RA-associated IP (n = 18), patients with idiopathic IP (n = 21), and control subjects (n = 11) were stained with antibodies to CD20 and CD138. Morphologic patterns of stained specimens were characterized and staining was quantified using computer-assisted image analysis.
RESULTS: In RA-associated IP, marked follicular B cell hyperplasia was detected, which was limited almost entirely to peribronchiolar lymphoid aggregates. Plasma cells were also present in large numbers, but showed a more diffuse tissue infiltration. Quantification of B cells demonstrated higher cellularity in RA-associated IP (median 2.0%, interquartile range [IQR] 1.0-5.7) as compared with idiopathic IP (0.9%, IQR 0.5-2.1). Control specimens showed a significantly smaller number of B cells compared with both diseases (0.4%, IQR 0.1-1.3). In RA patients who were smokers and in those who were male, the proportion of CD20+ tissue areas further increased to 4.3% (IQR 1.0-5.8) and 3.9% (IQR 0.7-6.9), respectively.
CONCLUSION: We demonstrated a significant follicular B cell hyperplasia in RA-associated IP. The differences between RA-associated IP and idiopathic IP imply a differential emphasis of B cell-mediated mechanisms in the 2 diseases despite radiologic and histologic similarities and provide a rationale for studying functional aspects of B cell involvement in the pathogenesis of RA-associated IP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16447242     DOI: 10.1002/art.21758

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

Review 1.  Comprehensive review of current diagnostic and treatment approaches to interstitial lung disease associated with rheumatoid arthritis.

Authors:  Cemal Bes
Journal:  Eur J Rheumatol       Date:  2018-07-01

2.  Targeting B lymphocytes in progressive fibrosing mediastinitis.

Authors:  Blair D Westerly; Geoffrey B Johnson; Fabien Maldonado; James P Utz; Ulrich Specks; Tobias Peikert
Journal:  Am J Respir Crit Care Med       Date:  2014-11-01       Impact factor: 21.405

3.  Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.

Authors:  Md Yuzaiful Md Yusof; Angela Kabia; Michael Darby; Giovanni Lettieri; Paul Beirne; Edward M Vital; Shouvik Dass; Paul Emery
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

Review 4.  The development and function of mucosal lymphoid tissues: a balancing act with micro-organisms.

Authors:  T D Randall; R E Mebius
Journal:  Mucosal Immunol       Date:  2014-02-26       Impact factor: 7.313

Review 5.  The Complex Role of the Lung in the Pathogenesis and Clinical Outcomes of Rheumatoid Arthritis.

Authors:  Lindsay B Kelmenson; M Kristen Demoruelle; Kevin D Deane
Journal:  Curr Rheumatol Rep       Date:  2016-11       Impact factor: 4.592

Review 6.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

7.  Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data.

Authors:  Alejandro Robles-Perez; Jordi Dorca; Ivan Castellví; Joan Miquel Nolla; Maria Molina-Molina; Javier Narváez
Journal:  Rheumatol Int       Date:  2020-03-10       Impact factor: 2.631

Review 8.  Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.

Authors:  Eunice J Kim; Harold R Collard; Talmadge E King
Journal:  Chest       Date:  2009-11       Impact factor: 9.410

9.  Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.

Authors:  Mitsuhiro Akiyama; Yuko Kaneko; Kunihiro Yamaoka; Harumi Kondo; Tsutomu Takeuchi
Journal:  Rheumatol Int       Date:  2016-04-12       Impact factor: 2.631

Review 10.  Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations.

Authors:  Tihong Shao; Xiaodong Shi; Shanpeng Yang; Wei Zhang; Xiaohu Li; Jingwei Shu; Shehabaldin Alqalyoobi; Amir A Zeki; Patrick S Leung; Zongwen Shuai
Journal:  Front Immunol       Date:  2021-06-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.